STG 175
Alternative Names: STG-175Latest Information Update: 28 Dec 2020
Price :
$50 *
At a glance
- Originator S & T Global
- Class Anti-infectives; Antivirals; Small molecules
- Mechanism of Action Cyclophilin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
- 11 Nov 2016 Preclinical trials in Hepatitis B in USA before November 2016
- 11 Nov 2016 Preclinical data in Hepatitis B presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2016)